|Videos|December 4, 2020
HIV Treatment Adherence and COVID-19
Advertisement
Episodes in this series
Dr Moti Ramgopal discusses current rates of adherence to HIV treatments during the COVID-19 pandemic and explains how his clinic is working to address barriers and best support patients.
Advertisement
Related to this article
Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
A meta-analysis of HELIOS-B and CARDIO-TTRansform found gene silencers reduced death and CV events, driven by patients not taking stabilizers.
ApoB more directly reflects atherogenic particle burden than LDL-C, but missing outcome trials and assay variability still limit its routine use.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Advertisement
Advertisement
Trending on AJMC
1
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
2
5 Things to Know About the One Big Beautiful Bill Act
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5